Chemed 관리

관리 기준 확인 3/4

Chemed CEO는 Kevin McNamara, Aug1994 에 임명되었습니다 의 임기는 30.75 년입니다. 총 연간 보상은 $ 12.77M, 13.6% 로 구성됩니다. 13.6% 급여 및 86.4% 보너스(회사 주식 및 옵션 포함). 는 $ 58.68M 가치에 해당하는 회사 주식의 0.69% 직접 소유합니다. 58.68M. 경영진과 이사회의 평균 재임 기간은 각각 25 년과 16 년입니다.

주요 정보

Kevin McNamara

최고 경영자

US$12.8m

총 보상

CEO 급여 비율	13.61%
CEO 임기	30.8yrs
CEO 소유권	0.7%
경영진 평균 재임 기간	25yrs
이사회 평균 재임 기간	16yrs

최근 관리 업데이트

Recent updates

Here's What Analysts Are Forecasting For Chemed Corporation (NYSE:CHE) After Its First-Quarter Results

May 01

Why You Should Care About Chemed's (NYSE:CHE) Strong Returns On Capital

Apr 22

Here's Why We Think Chemed (NYSE:CHE) Is Well Worth Watching

Apr 07

Chemed Corporation's (NYSE:CHE) Intrinsic Value Is Potentially 61% Above Its Share Price

Mar 21

Chemed Corporation's (NYSE:CHE) Popularity With Investors Is Clear

Mar 06

Investors Shouldn't Overlook The Favourable Returns On Capital At Chemed (NYSE:CHE)

Jan 03

With EPS Growth And More, Chemed (NYSE:CHE) Makes An Interesting Case

Dec 18

Is There An Opportunity With Chemed Corporation's (NYSE:CHE) 25% Undervaluation?

Dec 03

The Chemed Corporation (NYSE:CHE) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 01

Chemed Corporation's (NYSE:CHE) Business Is Yet to Catch Up With Its Share Price

Oct 29

Capital Investments At Chemed (NYSE:CHE) Point To A Promising Future

Aug 26

Strategic Acquisitions And Operational Efficiencies Set To Propel VITAS And Roto-Rooter Forward

Aug 25 Strategic acquisitions, such as Covenant Health, and aggressive hiring in VITAS are poised to enhance Chemed's revenue and net margins through improved operational efficiency.

Chemed: Still Bullish On Economic Characteristics, But Risks Shouldn't Be Overlooked

Aug 13

CEO 보상 분석

Kevin McNamara 의 보수는 Chemed 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2025	n/a	n/a	US$309m
Dec 31 2024	US$13m	US$2m	US$302m
Sep 30 2024	n/a	n/a	US$302m
Jun 30 2024	n/a	n/a	US$301m
Mar 31 2024	n/a	n/a	US$283m
Dec 31 2023	US$13m	US$2m	US$273m
Sep 30 2023	n/a	n/a	US$245m
Jun 30 2023	n/a	n/a	US$226m
Mar 31 2023	n/a	n/a	US$240m
Dec 31 2022	US$12m	US$1m	US$250m
Sep 30 2022	n/a	n/a	US$262m
Jun 30 2022	n/a	n/a	US$277m
Mar 31 2022	n/a	n/a	US$267m
Dec 31 2021	US$12m	US$1m	US$269m
Sep 30 2021	n/a	n/a	US$308m
Jun 30 2021	n/a	n/a	US$303m
Mar 31 2021	n/a	n/a	US$329m
Dec 31 2020	US$12m	US$1m	US$319m
Sep 30 2020	n/a	n/a	US$271m
Jun 30 2020	n/a	n/a	US$263m
Mar 31 2020	n/a	n/a	US$231m
Dec 31 2019	US$10m	US$1m	US$220m
Sep 30 2019	n/a	n/a	US$209m
Jun 30 2019	n/a	n/a	US$201m
Mar 31 2019	n/a	n/a	US$205m
Dec 31 2018	US$9m	US$1m	US$206m

보상 대 시장: Kevin 의 총 보상 ($USD 12.77M )은 US 시장( $USD 8.54M ).

보상과 수익: Kevin 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Kevin McNamara (70 yo)

30.8yrs

테뉴어

US$12,769,564

보상

Mr. Kevin J. McNamara has been the Chief Executive Officer of Chemed Corporation since May 2001 and President since August 2, 1994. Mr. McNamara served as an Executive Vice President and Secretary of Cheme...

리더십 팀

이름	위치	테뉴어	보상	소유권
Kevin McNamara	CEO, President & Director	30.8yrs	US$12.77m	0.69% $ 58.7m
Michael Witzeman	VP, Controller	13yrs	US$3.49m	0.039% $ 3.3m
Brian Judkins	VP, Secretary & Chief Legal Officer	4.8yrs	US$2.63m	0.015% $ 1.3m
Spencer Lee	Executive Vice President	25yrs	US$2.95m	0.11% $ 9.4m
Thomas Hutton	VP & Director	37.3yrs	데이터 없음	0.55% $ 46.7m
Nicholas Westfall	Executive Vice President	8.9yrs	US$5.14m	0.069% $ 5.8m
Nathan McNamara	VP & Chief Strategy Officer	no data	데이터 없음	데이터 없음
Lisa Reinhard	VP, Chief Administrative Officer & Secretary	30.5yrs	데이터 없음	데이터 없음
Sherri Warner	Director of Investor Relations	no data	데이터 없음	데이터 없음

25.0yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: CHE 의 관리팀은 노련하고 경험 (평균 재직 기간 25 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Kevin McNamara	CEO, President & Director	38.3yrs	US$12.77m	0.69% $ 58.7m
Thomas Hutton	VP & Director	40.3yrs	데이터 없음	0.55% $ 46.7m
Thomas Rice	Independent Director	16yrs	US$281.77k	데이터 없음
Sandra Laney	Director Emeritus	16yrs	US$157.02k	데이터 없음
Patrick Grace	Independent Director	29.3yrs	US$313.77k	0.022% $ 1.9m
George Walsh	Independent Chairman	30.3yrs	US$480.85k	0.021% $ 1.8m
Andrea Lindell	Independent Director	17yrs	US$276.27k	0.039% $ 3.3m
Christopher Heaney	Independent Director	5yrs	US$284.27k	0.014% $ 1.2m
Ron DeLyons	Independent Director	5yrs	US$281.77k	0.0095% $ 805.4k
John Mount	Independent Director	2.8yrs	US$281.77k	0.0045% $ 378.6k
Eileen McCarthy	Independent Director	2yrs	US$276.27k	0.0040% $ 335.5k

16.0yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: CHE 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 16 년).

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/19 15:02
장 마감 주가	2025/05/16 00:00
수익	2025/03/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Chemed Corporation 12 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Ishan Majumdar	Baptista Research
Adam Feinstein	Barclays
Joanna Sylvia Gajuk	BofA Global Research

Chemed 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Executive Vice President recently sold US$867k worth of stock

CEO, President & Director exercised options and sold US$1.0m worth of stock

Chemed Corporation, Annual General Meeting, May 19, 2025

CEO, President & Director recently sold US$615k worth of stock

CEO, President & Director notifies of intention to sell stock

VP, Controller exercised options and sold US$1.2m worth of stock

Recent updates

Executive Vice President recently sold US$867k worth of stock

CEO, President & Director exercised options and sold US$1.0m worth of stock

Here's What Analysts Are Forecasting For Chemed Corporation (NYSE:CHE) After Its First-Quarter Results

First quarter 2025 earnings: EPS misses analyst expectations

Why You Should Care About Chemed's (NYSE:CHE) Strong Returns On Capital

Here's Why We Think Chemed (NYSE:CHE) Is Well Worth Watching

Chemed Corporation, Annual General Meeting, May 19, 2025

CEO, President & Director recently sold US$615k worth of stock

CEO, President & Director notifies of intention to sell stock

Chemed Corporation to Report Q1, 2025 Results on Apr 23, 2025

Chemed Corporation's (NYSE:CHE) Intrinsic Value Is Potentially 61% Above Its Share Price

VP, Controller exercised options and sold US$1.2m worth of stock

CEO, President & Director notifies of intention to sell stock

Chemed Corporation's (NYSE:CHE) Popularity With Investors Is Clear

Executive Vice President recently sold US$785k worth of stock

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Third quarter dividend of US$0.50 announced

Chemed Corporation Declares Quarterly Dividend, Payable on March 14, 2025

Chemed Corporation to Report Q4, 2024 Results on Feb 26, 2025

Investors Shouldn't Overlook The Favourable Returns On Capital At Chemed (NYSE:CHE)

With EPS Growth And More, Chemed (NYSE:CHE) Makes An Interesting Case

Is There An Opportunity With Chemed Corporation's (NYSE:CHE) 25% Undervaluation?

CEO, President & Director notifies of intention to sell stock

Executive Vice President recently sold US$566k worth of stock

Third quarter dividend of US$0.50 announced

Chemed Corporation Declares Quarterly Dividend, Payable on December 6, 2024

The Chemed Corporation (NYSE:CHE) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Third quarter 2024 earnings: EPS misses analyst expectations

Now 29% undervalued after recent price drop

Chemed Corporation Revises Consolidated Earnings Guidance for the Full Year 2024

Chemed Corporation's (NYSE:CHE) Business Is Yet to Catch Up With Its Share Price

CEO, President & Director recently sold US$1.2m worth of stock

Chemed Corporation to Report Q3, 2024 Results on Oct 29, 2024

Executive Vice President recently sold US$975k worth of stock

Executive Vice President exercised options and sold US$1.6m worth of stock

Capital Investments At Chemed (NYSE:CHE) Point To A Promising Future

Strategic Acquisitions And Operational Efficiencies Set To Propel VITAS And Roto-Rooter Forward

Chemed Remains A Buy On Long-Term Economics

VP & Director notifies of intention to sell stock

Second quarter dividend increased to US$0.50

Chemed Corporation Declares Quarterly Dividend, Payable on August 30, 2024

Executive Vice President recently sold US$1.1m worth of stock

Executive Vice President notifies of intention to sell stock

Second quarter 2024 earnings: EPS misses analyst expectations

Chemed Corporation's (NYSE:CHE) Shares May Have Run Too Fast Too Soon

Chemed Corporation to Report Q2, 2024 Results on Jul 24, 2024

CEO, President & Director recently sold US$816k worth of stock

CEO, President & Director notifies of intention to sell stock

First quarter dividend of US$0.40 announced

Chemed Corporation Declares Quarterly Dividend, Payable on June 18, 2024

Chemed: Growth Does Not Justify The Current Stock Price

CEO, President & Director recently sold US$2.3m worth of stock

Chemed Corporation Reiterates Earnings Guidance for Full Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Chemed Corporation, Annual General Meeting, May 20, 2024

New major risk - Revenue and earnings growth

Executive Vice President exercised options and sold US$3.8m worth of stock

Executive Vice President recently sold US$1.3m worth of stock

Chemed Corporation to Report Q1, 2024 Results on Apr 24, 2024

Price target increased by 10% to US$690

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Now 22% overvalued after recent price rise

Third quarter dividend of US$0.40 announced

Chemed Corporation Declares Quarterly Dividend, Payable on March 15, 2024

Chemed Corporation to Report Q4, 2023 Results on Feb 27, 2024

Chemed Corporation Appoints Michael D. Witzeman as Chief Financial Officer, Effective January 1, 2024

CEO, President & Director recently sold US$859k worth of stock

Chemed: Continues To Compound Shareholder Value At Double-Digit Returns

Executive Vice President recently sold US$580k worth of stock